Zealand announces confirmatory Phase III results in hypoglycaemia

Zealand has a peptide-focused approach to drug development for hypoglycaemia and related conditions, short bowel syndrome and obesity associated with type 2 diabetes. Credit: Zealand Pharma.



  • Zealand hypoglycaemia